Oncolytics Biotech (NASDAQ:ONCY) Insider Thomas Charles Heineman Purchases 12,132 Shares of Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) insider Thomas Charles Heineman acquired 12,132 shares of the company’s stock in a transaction on Thursday, February 12th. The stock was acquired at an average cost of $0.83 per share, for a total transaction of $10,069.56. Following the completion of the purchase, the insider directly owned 282,818 shares of the company’s stock, valued at approximately $234,738.94. This represents a 4.48% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Oncolytics Biotech Price Performance

NASDAQ:ONCY opened at $1.06 on Friday. Oncolytics Biotech Inc. has a one year low of $0.33 and a one year high of $1.51. The company has a market cap of $112.52 million, a PE ratio of -3.79 and a beta of 0.99. The firm has a 50-day moving average of $0.98 and a 200-day moving average of $1.07.

Oncolytics Biotech (NASDAQ:ONCY) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. On average, equities research analysts expect that Oncolytics Biotech Inc. will post -0.28 earnings per share for the current fiscal year.

Key Stories Impacting Oncolytics Biotech

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
• Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
• Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
• Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
• Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
• Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
• Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
• Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
• Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

Institutional Investors Weigh In On Oncolytics Biotech

A number of hedge funds have recently made changes to their positions in the business. Scientech Research LLC purchased a new position in shares of Oncolytics Biotech in the 3rd quarter worth about $25,000. Security National Bank of Sioux City Iowa IA purchased a new stake in Oncolytics Biotech during the fourth quarter worth about $29,000. Ground Swell Capital LLC bought a new stake in Oncolytics Biotech in the fourth quarter worth about $30,000. CIBC Private Wealth Group LLC purchased a new position in Oncolytics Biotech in the fourth quarter valued at about $44,000. Finally, Tocqueville Asset Management L.P. bought a new position in shares of Oncolytics Biotech during the 4th quarter valued at approximately $63,000. 6.82% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. HC Wainwright upped their price target on Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, November 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncolytics Biotech in a report on Monday, December 29th. Wall Street Zen lowered shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, Zacks Research raised shares of Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $6.25.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.